Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.54 USD
-0.10 (-0.86%)
Updated Jul 26, 2024 01:54 PM ET
After-Market: $11.52 -0.02 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVTX 11.54 -0.10(-0.86%)
Will AVTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVTX
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
AVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for AVTX
The 3 Best Personalized Nutrition Stocks to Buy Now
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
Avalo Therapeutics appoints Doyle as Chief Medical Officer
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1? mAb, to Treat Hidradenitis Suppurativa
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer